This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patients. CNAs ...
GEORGIA AVENUE, WA, UNITED STATES, October 17, 2024 /EINPresswire / -- The latest release from Vantage <a target=_blank href= ...
This technology quickly and sensitively detects metabolites and changes in cancer patients' body fluids, providing a non-invasive way to diagnose cancer instead of traditional blood draws or biopsies.